Home » CELERA SELLS DRUG PROGRAM TO SCHERING AG
CELERA SELLS DRUG PROGRAM TO SCHERING AG
Celera Genomics has gotten out of the drug-development business. The Rockville-based biotechnology company said Wednesday it sold a small-molecule drug program for the treatment of autoimmune diseases to German pharmaceutical giant Schering AG.
Washington Business Journal
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May